# Hepatic Arterial Infusion Chemotherapy and Immunotherapy for Hepatocellular Carcinoma

> **NCT06741020** · PHASE1,PHASE2 · RECRUITING · sponsor: **Zhejiang Cancer Hospital** · enrollment: 10 (estimated)

## Conditions studied

- Hepatocellular Carcinoma (HCC)

## Interventions

- **DRUG:** Adebrelimab, Oxaliplatin, Fluorouracil,Leucovorin

## Key facts

- **NCT ID:** NCT06741020
- **Lead sponsor:** Zhejiang Cancer Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-03-01
- **Primary completion:** 2026-06-30
- **Final completion:** 2026-12-30
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2025-05-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06741020

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06741020, "Hepatic Arterial Infusion Chemotherapy and Immunotherapy for Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06741020. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*